Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC
Clinical trial NCT07145450 · RECRUITING
Trial details
- NCT number
- NCT07145450
- Sponsor
- Anocca AB
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-03
- Primary completion
- 2030-04-02
- Enrollment
- 96
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.